



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICANT : JACKOWSKI et al.

INVENTION: : BIOPOLYMER MARKER INDICATIVE OF DISEASE STATE HAVING A MOLECULAR WEIGHT OF 1518 DALTONS

SERIAL NUMBER : 09/845,765

FILING DATE : 04/30/01

EXAMINER: : (not assigned yet)

GROUP ART UNIT : 1616

ATTORNEY DOCKET NO. : 2132.036

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

CERTIFICATE UNDER 37 CFR 1.8(a)
I hereby certify that this correspondence is being deposited with the U.S. Postal Service as First Class mail in an envelope addressed to Commissioner for Patents, Washington, D.C. 20231 on 12/9/02
Susan Hess

Commissioner for Patents
Washington, D.C. 20231

Sir:

Pursuant to the Duty to Disclose under 37 C.F.R. §1.56, the references cited on the accompanying form PTO-1449 are hereby brought to the attention of the Examiner for independent evaluation. A copy of each reference is enclosed. The references were cited in an International Search Report of the European Patent Office in the corresponding patent application.

A copy of the International Search Report is also enclosed, which satisfies the requirement for a concise statement of relevancy pursuant to M.P.E.P. §609 (1995).

Applicants submit that the present invention is patentable over these references.

Date: 12/9/2002

Respectfully Submitted,

Ferris H. Lander
Ferris H. Lander
Reg. No. 43,377
McHale & Slavin, P.A.
4440 PGA Boulevard, Suite 402
Palm Beach Gardens, FL 33410
Telephone: (561) 625-6575

RECEIVED
DEC 17 2002
TECH CENTER 1600/2900



RECEIVED
DEC 17 2002
TECH CENTER 1600/2900
#4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICANT : JACKOWSKI et al.

INVENTION: : BIOPOLYMER MARKER INDICATIVE OF DISEASE STATE HAVING A MOLECULAR WEIGHT OF 1518 DALTONS

SERIAL NUMBER : 09/845,765

FILING DATE : 04/30/01

EXAMINER: : (not assigned yet)

GROUP ART UNIT : 1616

ATTORNEY DOCKET NO. : 2132.036

TRANSMITTAL LETTER

CERTIFICATE UNDER 37 CFR 1.8(a)

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as First Class mail in an envelope addressed to Commissioner for Patents, Washington, D.C. 20231 on 12/9/02

Susan Hess

Commissioner for Patents
Washington, D.C. 20231

Sir:

Please find enclosed for filing:

Supplemental Information Disclosure Statement
 Certification Pursuant to 37 C.F.R. §1.97(e)
 Copy of International Search Report
 PTO-1449
 References

Respectfully Submitted,

Ferris H. Lander

Ferris H. Lander
Reg. No. 43,377
McHale & Slavin, P.A.
4440 PGA Boulevard, Suite 402
Palm Beach Gardens, FL 33410
Telephone: (561) 625-6575

Date: 12/9/2002



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICANT : JACKOWSKI et al.

INVENTION: : BIOPOLYMER MARKER INDICATIVE OF DISEASE STATE HAVING A MOLECULAR WEIGHT OF 1518 DALTONS

SERIAL NUMBER : 09/845,765

FILING DATE : 04/30/01

EXAMINER: : (not assigned yet)

GROUP ART UNIT : 1616

ATTORNEY DOCKET NO. : 2132.036

CERTIFICATION PURSUANT TO 37 C.F.R. §1.97 (e)

CERTIFICATE UNDER 37 CFR 1.8(a)
I hereby certify that this correspondence is being
deposited with the U.S. Postal Service as First Class mail
in an envelope addressed to Commissioner for
Patents, Washington, D.C. 20231 on 12/9/02

Severin Lander

Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with 37 C.F.R. §1.97(e), Applicants hereby certify that each item of information contained in the accompanying Supplemental Information Disclosure Statement filed concurrently herewith was cited in a communication from a foreign patent office, namely an International Search Report for a counterpart European patent application, not more than three months prior to the filing of the accompanying Supplemental Information Disclosure Statement.

Accordingly, pursuant to 37 C.F.R. §1.97(e), Applicants request consideration and entry of the Supplemental Information Disclosure Statement.

Date: 12/9/2002

Respectfully Submitted,

Ferris H. Lander
Ferris H. Lander
Reg. No. 43,377
McHale & Slavin, P.A.
4440 PGA Boulevard, Suite 402
Palm Beach Gardens, FL 33410
Telephone: (561) 625-6575

RECEIVED
DEC 17 2002
TECH CENTER 1600/2900



RECEIVED
DEC 17 2002

TECH CENTER 1600/2900

Sheet 1 of 1

| | | | | |
|--|--|--|------------------------------|-------------------------------|
| Form PTO-1449 (Rev. 2-88) | | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | ATTY. DOCKET NO. 2132.036 | APPLICATION NO. 09/845,765 |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i> | | APPLICANT JACKOWSKI et al. | | |
| | | FILING DATE 04/30/01 | GROUP 1616 | |

U.S. PATENT DOCUMENTS

| EXAMINER'S INITIAL | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE | |
|--------------------|-----------------|-------|-------------------|-------|----------|----------------------------|----|
| | | | | | | YES | NO |
| | 5,827,659 | 10/98 | Patterson | | | | |
| | 5,817,768 | 10/98 | Grieninger et al. | | | | |
| | 5,538,897 | 07/96 | Yates, III et al. | | | | |
| | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION | |
| | | | | | | YES | NO |
| | WO 96/14580 | 05/96 | PCT | | | X | |
| | WO 00/09562 | 02/00 | PCT | | | X | |
| | WO 01/05422 | 01/01 | PCT | | | | X |
| | WO 00/49410 | 08/00 | PCT | | | X | |
| | WO 01/75454 | 10/01 | PCT | | | X | |
| | | | | | | | |

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

| | | |
|--|--|--|
| | | Sobel, et al., "Antipeptide Monoclonal Antibodies to Defined Fibrinogen A α Chain Regions: Anti-A α 487-498, a Structural Probe for Fibrinogenolysis", Blood (1998), Vol. 91, No. 5, pp. 1590-1598. |
| | | Scharfstein, et al., "Usefulness of Fibrinogenolytic and Procoagulant Markers During Thrombolytic Therapy in Predicting Clinical Outcomes in Acute Myocardial Infarction", Am. Journal of Cardiology (1996), Vol. 78, No. 5, pp. 503-510. |
| | | Database Entrez-Protein Online!, "Fibrinogen Alpha", National Center for Biotechnology Information (NCBI), June 15 (2000), Disclosed FPA sequence: aa 20-35, retrieved from www.ncbi.nlm.nih.gov . |

| | |
|----------|-----------------|
| EXAMINER | DATE CONSIDERED |
|----------|-----------------|

* EXAMINER: Initial if a citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.